161 related articles for article (PubMed ID: 3163417)
1. Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer.
Nishida K; Miyagawa H; Yoshikawa T; Kondo M
Oncology; 1988; 45(3):166-71. PubMed ID: 3163417
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue.
Takasaki H; Tempero MA; Uchida E; Büchler M; Ness MJ; Burnett DA; Metzgar RS; Colcher D; Schlom J; Pour PM
Int J Cancer; 1988 Nov; 42(5):681-6. PubMed ID: 3053465
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of neuron-specific enolase and CA 19-9 in pancreatic disorders. The value of neuron-specific enolase as a marker for islet cell and nerve tissue.
Iwase K; Kato K; Nagasaka A; Miura K; Kawase K; Miyakawa S; Tei T; Ohtani S; Inagaki M; Shinoda S
Gastroenterology; 1986 Sep; 91(3):576-80. PubMed ID: 3015709
[TBL] [Abstract][Full Text] [Related]
5. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
6. Expression of Tn, sialosyl Tn, and T antigens in human pancreas.
Itzkowitz S; Kjeldsen T; Friera A; Hakomori S; Yang US; Kim YS
Gastroenterology; 1991 Jun; 100(6):1691-700. PubMed ID: 1850375
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
Safi F; Büchler M; Schenkluhn B; Beger HG
Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
[TBL] [Abstract][Full Text] [Related]
10. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero MA; Uchida E; Takasaki H; Burnett DA; Steplewski Z; Pour PM
Cancer Res; 1987 Oct; 47(20):5501-3. PubMed ID: 3308077
[TBL] [Abstract][Full Text] [Related]
11. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor.
Tatsuta M; Yamamura H; Iishi H; Ichii M; Noguchi S; Yamamoto R; Okuda S
Cancer; 1985 Dec; 56(11):2669-73. PubMed ID: 3863691
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of a serum pancreatic tumor marker: the carbohydrate antigen C.A. 19-9].
Vincent D; Venot J; Catanzano G; Clément MN; Piquet MF; Veyriras E; Beck C
Ann Med Interne (Paris); 1985; 136(2):142-4. PubMed ID: 3865571
[TBL] [Abstract][Full Text] [Related]
13. Elevated tissue concentrations of sialyl Lex-i in cancerous tissues compared with those in noncancerous tissues of various organs.
Nishida K; Yamamoto H; Ohtsuki T; Matsuba M; Mukai S; Naito Y; Yoshikawa T; Kondo M
Cancer; 1991 Jul; 68(1):111-7. PubMed ID: 2049731
[TBL] [Abstract][Full Text] [Related]
14. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
[TBL] [Abstract][Full Text] [Related]
15. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
16. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
Heptner G; Domschke S; Schneider MU; Domschke W
Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
[TBL] [Abstract][Full Text] [Related]
17. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
Haglund C; Kuusela P; Jalanko H; Roberts PJ
Int J Cancer; 1987 Apr; 39(4):477-81. PubMed ID: 3470260
[TBL] [Abstract][Full Text] [Related]
20. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases.
Takiyama Y; Tempero MA; Takasaki H; Onda M; Tsuchiya R; Büchler M; Ness M; Colcher D; Schlom J; Pour PM
Hum Pathol; 1989 Sep; 20(9):832-8. PubMed ID: 2673979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
